litlas
Log inCreate account

Barbara Eichhorst

Active 2004–2025

119
Papers
19,275
Citations
61
h-index
115
i10-index

Citations

Citations per year for Barbara Eichhorst1979: 1 citations2003: 1 citations2005: 6 citations2006: 10 citations2007: 21 citations2008: 18 citations2009: 43 citations2010: 43 citations2011: 33 citations2012: 49 citations2013: 33 citations2014: 77 citations2015: 129 citations2016: 93 citations2017: 138 citations2018: 199 citations2019: 634 citations2020: 827 citations2021: 821 citations2022: 582 citations2023: 406 citations2024: 934 citations2025: 427 citations2026: 24 citations1980–2002: no citations, so these years are not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,126 citing papers, 20.8% of this breakdownItaly: 435 citing papers, 8.1% of this breakdownGermany: 432 citing papers, 8% of this breakdownUnited Kingdom: 384 citing papers, 7.1% of this breakdownChina: 268 citing papers, 5% of this breakdownFrance: 254 citing papers, 4.7% of this breakdownAustralia: 245 citing papers, 4.5% of this breakdownSpain: 224 citing papers, 4.2% of this breakdownNetherlands: 184 citing papers, 3.4% of this breakdownSwitzerland: 174 citing papers, 3.2% of this breakdownCanada: 151 citing papers, 2.8% of this breakdownPoland: 126 citing papers, 2.3% of this breakdown
0%20.8%Other 25.9%

Institutions

Fields

  • Medicine82.3%
  • Biochemistry, Genetics and Molecular Biology13.1%
  • Immunology and Microbiology2.9%
  • Computer Science0.4%
  • Chemistry0.2%
  • Economics, Econometrics and Finance0.2%
  • Other0.9%

Topics

  • Chronic Lymphocytic Leukemia Research21.3%
  • Lymphoma Diagnosis and Treatment13.5%
  • Immunodeficiency and Autoimmune Disorders5.8%
  • Chronic Myeloid Leukemia Treatments4.4%
  • CAR-T cell therapy research3.3%
  • Acute Myeloid Leukemia Research2.7%
  • Other49%

Coauthors

All papers

Open in search
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 cited by 1,689

  2. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte Yimer, Tommi Salmi, Megan-Der-Yu Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman - New England Journal of Medicine 2022 cited by 457

  3. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    Authors: Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha‐Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michaël Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna‐Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens‐Martin Wendtner, Karl Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark‐David Levin, Marinus van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek - New England Journal of Medicine 2023 cited by 291

  4. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Authors: Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 cited by 852

  5. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater - New England Journal of Medicine 2018 cited by 909

  6. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Authors: Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens‐Martin Wendtner, Tatiana Chagorova, Javier de la Serna, Marie‐Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn Owen, Olga Samoylova, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Hartmut Döhner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Michael Hallek - New England Journal of Medicine 2014 cited by 1,500

  7. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 cited by 796

  8. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    Authors: Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna‐Maria Fink, Sandra Robrecht, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens‐Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer - The Lancet Oncology 2020 cited by 327

  9. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater - Blood 2022 cited by 151

  10. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

    Authors: Daniel Thomalla, Laura Beckmann, Christina Grimm, Matteo Oliverio, Lydia Meder, Carmen Herling, Pascal Nieper, T. Feldmann, Olaf Merkel, Eva Lorsy, Alexandra da Palma Guerreiro, J. von Jan, Ilmars Kisis, Elena Wasserburger, Julia Claasen, E. Faitschuk-Meyer, Janine Altmüller, Peter Nürnberg, T.-P. Yang, Matthias Lienhard, Ralf Herwig, K.-A. Kreuzer, Christian P. Pallasch, Reinhard Büttner, Stephan Schäfer, John C. Hartley, Hinrich Abken, Martin Peifer, H. Kashkar, Gero Knittel, Barbara Eichhorst, Roland T. Ullrich, Marco Herling, Hans Christian Reinhardt, Michael Hallek, Michal R. Schweiger, Lukas P. Frenzel - Blood 2022 cited by 131

  11. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Authors: Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Nature Communications 2023 cited by 93

  12. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

    Authors: Arnon P. Kater, Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth A. Punnoose, Christopher R. Bolen, Zoe J. Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John F. Seymour - Journal of Clinical Oncology 2020 cited by 220

  13. Chronic lymphocytic leukaemia

    Authors: Michael Hallek, Tait D. Shanafelt, Barbara Eichhorst - The Lancet 2018 cited by 370

  14. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutré, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens‐Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Böttcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer A. Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda - Journal of Clinical Oncology 2018 cited by 313

  15. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    Authors: Othman Al‐Sawaf, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens‐Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Journal of Clinical Oncology 2021 cited by 142

  16. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

    Authors: Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer, Gábor Kovács, Marco Herling, Eugen Tausch, Karl-Anton Kreuzer, Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton, Michael Kneba, Clemens‐Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer, Michael Hallek - Blood 2015 cited by 700

  17. TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

    Authors: Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer - Journal of Clinical Oncology 2010 cited by 597

  18. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

    Authors: H. Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Othman Al‐Sawaf, Karl‐Anton Kreuzer, Anna‐Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer - Blood 2023 cited by 48

  19. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

    Authors: Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte Yimer, Tommi Salmi, Meng Ji, Jessica L. Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak - Journal of Clinical Oncology 2022 cited by 93

  20. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

    Authors: Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo, Raymonde Busch, Gábor Kovács, Christian Maurer, Elisabeth Lange, H. Köppler, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marek Trněný, Kirsten Fischer, Harmut Döhner, Michael Kneba, Clemens‐Martin Wendtner, Wolfgang Hiddemann, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Michael Hallek - The Lancet Oncology 2016 cited by 622

  21. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    Authors: Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven Coutré, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour - Blood 2019 cited by 175

  22. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

    Authors: Arnon P. Kater, John F. Seymour, Peter Hillmen, Barbara Eichhorst, Anton W. Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A. Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps - Journal of Clinical Oncology 2018 cited by 301

  23. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

    Authors: Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Blood 2024 cited by 127

  24. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

    Authors: Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al‐Sawaf, Julia von Tresckow, Anna‐Maria Fink, Karl‐Anton Kreuzer, Ursula Vehling‐Kaiser, Eugen Tausch, Lothar Müller, Michael J. Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens‐Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek - Blood 2021 cited by 93